## Anne Gompel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2210024/publications.pdf

Version: 2024-02-01

94 papers

4,345 citations

109264 35 h-index 63 g-index

102 all docs

 $\begin{array}{c} 102 \\ \\ \text{docs citations} \end{array}$ 

102 times ranked

4725 citing authors

#	Article	IF	CITATIONS
1	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3975-4011.	1.8	589
2	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Research and Treatment, 2012, 132, 895-915.	1.1	246
3	International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2012, 129, 308-320.	1.5	207
4	Progestin Effect on Cell Proliferation and $17\hat{l}^2$ -Hydroxysteroid Dehydrogenase Activity in Normal Human Breast Cells in Culture*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1174-1180.	1.8	173
5	Catamenial and Noncatamenial, Endometriosis-related or Nonendometriosis-related Pneumothorax Referred for Surgery. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1048-1053.	2.5	140
6	Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression. Cancer Research, 2006, 66, 6243-6249.	0.4	121
7	Catamenial pneumothorax and endometriosis-related pneumothorax: clinical features and risk factors. Human Reproduction, 2011, 26, 2322-2329.	0.4	97
8	The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor $\hat{l}_{\pm}$ modulation, uncoupling nuclear and membrane activation. EMBO Molecular Medicine, 2014, 6, 1328-1346.	3.3	96
9	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3647-3661.	1.8	89
10	Progestogen-Only Contraceptives and the Risk of Stroke. Stroke, 2009, 40, 1059-1062.	1.0	88
11	Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Annals of Allergy, Asthma and Immunology, 2013, 111, 290-294.	0.5	88
12	Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas, 2005, 51, 8-14.	1.0	87
13	Glucocorticoid receptor and breast cancer. Breast Cancer Research and Treatment, 2011, 130, 1-10.	1.1	85
14	The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie, 2011, 93, 1369-1378.	1.3	81
15	Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. , 1996, 68, 120-125.		76
16	The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. PLoS ONE, 2009, 4, e4223.	1.1	74
17	BRADYKININ RECEPTOR 2 ANTAGONIST (ICATIBANT) FOR HEREDITARY ANGIOEDEMA TYPE III ATTACKS. Annals of Allergy, Asthma and Immunology, 2009, 103, 448.	0.5	68
18	MECHANISMS IN ENDOCRINOLOGY: Epidemiology of hormonal contraceptives-related venous thromboembolism. European Journal of Endocrinology, 2014, 171, R221-R230.	1.9	67

#	Article	IF	CITATIONS
19	Neurotensin receptor 1 gene activation by the $Tcf \hat{l}^2$ -catenin pathway is an early event in human colonic adenomas. Carcinogenesis, 2006, 27, 708-716.	1.3	63
20	In vitro studies of tibolone in breast cells. Fertility and Sterility, 2002, 78, 351-359.	0.5	60
21	Progestogen-Only Contraceptives and the Risk of Acute Myocardial Infarction: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1169-1174.	1.8	58
22	Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception, 2011, 83, 229-237.	0.8	57
23	Pneumothorax in Women of Child-Bearing Age. Chest, 2014, 145, 354-360.	0.4	56
24	Estradiol/Progesterone Interaction in Normal and Pathologic Breast Cells. Annals of the New York Academy of Sciences, 1986, 464, 152-167.	1.8	55
25	Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. FEBS Journal, 2001, 268, 1352-1362.	0.2	54
26	Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Research and Treatment, 2012, 131, 49-63.	1.1	53
27	Study of Anti-M $\tilde{A}^1$ /4llerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3785-3792.	1.8	51
28	Progesterone and endometrial cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 69, 95-107.	1.4	49
29	Oral Contraceptives and Venous Thromboembolism Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009. Journal of Family Planning and Reproductive Health Care, 2010, 36, 117-122.	0.9	48
30	New NOBOX Mutations Identified in a Large Cohort of Women With Primary Ovarian Insufficiency Decrease KIT-L Expression. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 994-1001.	1.8	48
31	Contribution of Plasma Androstenedione to 5α-Androstanediol Glucuronide in Women with Idiopathic Hirsutism. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 441-444.	1.8	44
32	Neurotensin counteracts apoptosis in breast cancer cells. Biochemical and Biophysical Research Communications, 2002, 295, 482-488.	1.0	44
33	Focal Subnuclear Distribution of Progesterone Receptor Is Ligand Dependent and Associated with Transcriptional Activity. Molecular Endocrinology, 2007, 21, 14-29.	3.7	44
34	Pulmonary Lymphangiomyomatosis. Chest, 1992, 102, 472-476.	0.4	40
35	Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertility and Sterility, 1997, 68, 449-453.	0.5	40
36	Antiestrogens are pro-apoptotic in normal human breast epithelial cells. International Journal of Cancer, 2003, 105, 607-612.	2.3	40

#	Article	IF	Citations
37	Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Research and Treatment, 2015, 151, 309-318.	1.1	37
38	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. Oncotarget, 2014, 5, 8235-8251.	0.8	35
39	Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget, 2015, 6, 17621-17636.	0.8	32
40	Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism. Thrombosis and Haemostasis, 2018, 118, 922-928.	1.8	31
41	Death-Associated Protein Kinase Loss of Expression Is a New Marker for Breast Cancer Prognosis. Clinical Cancer Research, 2004, 10, 3124-3130.	3.2	30
42	Thoracic Endometriosis Syndrome Other Than Pneumothorax: Clinical and Pathological Findings. Annals of Thoracic Surgery, 2017, 104, 1865-1871.	0.7	30
43	Next Generation Sequencing Should Be Proposed to Every Woman With "ldiopathic―Primary Ovarian Insufficiency. Journal of the Endocrine Society, 2021, 5, bvab032.	0.1	30
44	Endometrial safety and tolerability of AERODIOL® (intranasal estradiol) for 1 year. Maturitas, 2000, 36, 209-215.	1.0	29
45	Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology. Annales D'Endocrinologie, 2012, 73, 469-487.	0.6	29
46	Progesterone, progestins and the breast in menopause treatment. Climacteric, 2018, 21, 326-332.	1.1	29
47	Estradiol stimulates c-myc proto-oncogene expression in normal human breast epithelial cells in culture. Journal of Steroid Biochemistry and Molecular Biology, 1995, 52, 299-305.	1.2	27
48	Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Immunity, Inflammation and Disease, 2017, 5, 29-36.	1.3	27
49	Ulipristal acetate does not impact human normal breast tissue. Human Reproduction, 2012, 27, 2785-2798.	0.4	25
50	Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies. Journal of Family Planning and Reproductive Health Care, 2013, 39, 80-88.	0.9	25
51	Life-Threatening Endometriosis-Related Hemopneumothorax. Annals of Thoracic Surgery, 2006, 82, 726-729.	0.7	24
52	Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort. European Journal of Dermatology, 2017, 27, 155-159.	0.3	24
53	Screening for familial cancer risk: Focus on breast cancer. Maturitas, 2017, 105, 69-77.	1.0	24
54	Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Climacteric, 2018, 21, 321-325.	1.1	24

#	Article	IF	Citations
55	Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: a report of three cases. Lupus, 1999, 8, 482-485.	0.8	23
56	Association of menopause and hormone replacement therapy with large artery remodeling. Fertility and Sterility, 2011, 96, 1445-1450.	0.5	23
57	Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Research and Treatment, 2013, 142, 283-296.	1.1	22
58	Suicide HSVtk Gene Delivery by Neurotensin-Polyplex Nanoparticles via the Bloodstream and GCV Treatment Specifically Inhibit the Growth of Human MDA-MB-231 Triple Negative Breast Cancer Tumors Xenografted in Athymic Mice. PLoS ONE, 2014, 9, e97151.	1.1	22
59	Management of granulomatous mastitis: a series of 14 patients. Gynecological Endocrinology, 2012, 28, 921-924.	0.7	21
60	Exogenous hormones and hereditary angioedema. International Immunopharmacology, 2020, 78, 106080.	1.7	21
61	Rationale, design and methods of the CASHMERE study+. Fundamental and Clinical Pharmacology, 2004, 18, 131-138.	1.0	19
62	Progestins induce catalase activities in breast cancer cells through PRB isoform: Correlation with cell growth inhibition. Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 153-160.	1.2	18
63	Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6516-6528.	3.2	18
64	Transient secondary amenorrhea in women treated by thalidomide. European Journal of Dermatology, 2002, 12, 63-5.	0.3	18
65	Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Annals of Allergy, Asthma and Immunology, 2015, 114, 499-503.	0.5	14
66	Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with <i>BRCA1</i> mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited <i>BRCA1</i> mutations. Oncotarget, 2016, 7, 45317-45330.	0.8	14
67	Difficult management of recurrent catamenial pneumothorax. Gynecological Endocrinology, 2006, 22, 713-715.	0.7	13
68	Contraception in cancer survivors – an expert review Part I. Breast and gynaecological cancers. European Journal of Contraception and Reproductive Health Care, 2019, 24, 167-174.	0.6	13
69	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. Cancer Letters, 2019, 444, 147-161.	3.2	13
70	Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 521-530.	1.4	10
71	Systemic lupus erythematosus and menopause. Climacteric, 2020, 23, 109-115.	1.1	10
72	The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy. Maturitas, 2007, 56, 227-229.	1.0	9

#	Article	IF	Citations
73	Effect of Estradiol and the Synthetic Progestin Promegestone (R5020) on the Proliferation of Human Mammary Cells in Culture. Annals of the New York Academy of Sciences, 1986, 464, 489-492.	1.8	8
74	Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study. Maturitas, 2006, 55, 1-4.	1.0	8
75	Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. Breast Cancer Research and Treatment, 2008, 111, 343-351.	1.1	8
76	Cognitive impairment in women with joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. Rheumatology International, 2017, 37, 937-939.	1.5	7
77	Contraception in cancer survivors – an expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers. European Journal of Contraception and Reproductive Health Care, 2019, 24, 299-304.	0.6	7
78	Micronized progesterone, progestins, and menopause hormone therapy. Women and Health, 2021, 61, 3-14.	0.4	7
79	Hereditary angioedema, emergency management of attacks by a call center. European Journal of Internal Medicine, 2019, 67, 42-46.	1.0	6
80	Apoptosis and aging: breast cells and apoptosis. Maturitas, 2001, 38, 39-44.	1.0	5
81	Complete Kisspeptin Receptor Inactivation Does Not Impede Exogenous GnRH-Induced LH Surge in Humans. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4482-4490.	1.8	5
82	Inhibin A and inhibin B producing ovarian fibrothecoma revealed by suppression of follicle stimulating hormone (FSH) in a post-menopausal woman: report of the first case. Gynecological Endocrinology, 2016, 32, 872-874.	0.7	4
83	Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women. Journal of Clinical Immunology, 2021, 41, 163-170.	2.0	4
84	Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill. Hormone Molecular Biology and Clinical Investigation, 2010, 3, 441-447.	0.3	3
85	Combined Hormonal Contraceptives and First Venous Thrombosis in Young French Women: Impact of Thrombotic Family History. Journal of the Endocrine Society, 2017, 1, 762-771.	0.1	3
86	Hereditary angioedema: Clinical presentation and socioeconomic cost of 200 French patients. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 328-330.	2.0	3
87	Antihypertensive Medications and Breast Cancer Risk. JAMA Internal Medicine, 2014, 174, 640.	2.6	1
88	Are we overestimating the stroke risk related to contraceptive pills?. Current Opinion in Neurology, 2014, 27, 29-34.	1.8	0
89	Progesterone and Synthetic Progestin Controversies. JAMA Oncology, 2015, 1, 987.	3.4	0
90	Clinical characteristics and response to attack treatment with Berinert® of drug induced angioedema in the French Cohort COBRA Journal of Allergy and Clinical Immunology, 2017, 139, AB236.	1.5	0

## Anne Gompel

#	Article	IF	CITATIONS
91	Estrogen on the breast Yin or Yan?. Maturitas, 2019, 124, 120.	1.0	0
92	Ménopause et maladies auto-immunes. La Presse Médicale Formation, 2020, 1, 60-66.	0.1	0
93	Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101756.	0.7	0
94	HRT, body mass index and breast cancer risk. Climacteric, 2014, 17, 98-9.	1.1	0